Jpmorgan Chase & CO Tyra Biosciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 368,647 shares of TYRA stock, worth $4.92 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
368,647
Previous 364,751
1.07%
Holding current value
$4.92 Million
Previous $5.83 Million
48.59%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding TYRA
# of Institutions
103Shares Held
47.3MCall Options Held
353KPut Options Held
1.1K-
Ra Capital Management, L.P. Boston, MA10.4MShares$139 Million3.41% of portfolio
-
Boxer Capital, LLC San Diego, CA6.45MShares$86.1 Million8.05% of portfolio
-
Bvf Inc San Francisco, CA4.66MShares$62.2 Million3.48% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.18MShares$55.8 Million97.27% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY4.08MShares$54.5 Million89.47% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $560M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...